NCT01752400View on ClinicalTrials.gov

AUY922 for Advanced ALK-positive NSCLC

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

June 30, 2017

Study Completion Date

November 30, 2017

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

AUY922

Trial Locations (4)

02114

Massachusetts General Hospital, Boston

02215

Beth Isreal Deaconess Medical Center, Boston

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT01752400 - AUY922 for Advanced ALK-positive NSCLC | Biotech Hunter | Biotech Hunter